Yao Zhicheng, Gan Fengping, Zeng Yuqing, Ren Litong, Zeng Yirong
The First Clinical Medical School, Guangzhou University of Chinese Medicine, China.
Shenzhen Hospital, Beijing University of Chinese Medicine, China.
Heliyon. 2024 Mar 12;10(6):e27999. doi: 10.1016/j.heliyon.2024.e27999. eCollection 2024 Mar 30.
In this study, we explored the therapeutic potential of Cyathula Officinals (CNX) in Knee Osteoarthritis (KOA) treatment. Utilizing network pharmacology and in vitro experiments, we identified active ingredients, action targets and pathways in CNX. Our analysis, integrating databases like TCMSP, SwissTarget Prediction, Genecards, CTD, STRING, and DAVID, highlighted 396 action targets and 283 disease targets, pinpointing 64 intersection genes linked to KOA. The significant involvement of the MAPK and NF-κB pathways in CNX's anti-inflammatory action was validated through qPCR, which might underlie CNX's efficacy in inhibiting chondrocyte apoptosis and IL-6 expression. These findings suggest CNX's potential in KOA management, offering insights for its clinical application.
在本研究中，我们探讨了牛膝（CNX）在膝关节骨关节炎（KOA）治疗中的潜在治疗作用。利用网络药理学和体外实验，我们确定了CNX中的活性成分、作用靶点和途径。我们整合了中药系统药理学数据库（TCMSP）、瑞士靶点预测、基因卡片、比较毒理基因组学数据库（CTD）、STRING和DAVID等数据库进行分析，突出显示了396个作用靶点和283个疾病靶点，确定了64个与KOA相关的交集基因。通过qPCR验证了丝裂原活化蛋白激酶（MAPK）和核因子κB（NF-κB）途径在CNX抗炎作用中的重要参与，这可能是CNX抑制软骨细胞凋亡和白细胞介素-6（IL-6）表达疗效的基础。这些发现表明CNX在KOA治疗中的潜力，为其临床应用提供了见解。
